Why the study?
Although DOACs are the antithrombotic treatment of choice in NVAF irrespective of age, certain factors may limit their use in elderly patients with complex clinical conditions.
What is the expert consensus on the appropriateness of different oral anticoagulants (DOACs vs VKAs) in elderly patients (≥75 years) with non-valvular atrial fibrillation and complex clinical conditions?
What is the expert consensus on the appropriateness of different oral anticoagulants (DOACs vs VKAs) in elderly patients (≥75 years) with non-valvular atrial fibrillation and complex clinical conditions?
Multidisciplinary experts strongly agree that advanced age alone should not limit anticoagulation in NVAF, favouring apixaban and edoxaban across complex geriatric and clinical scenarios except in post-AMI intraventricular thrombus where VKAs remain preferred.
Answers are grounded in this paper and cite their sources.
Supports apixaban preference in most complex elderly NVAF cases; extends consensus guidance where trial data are limited.
Non-valvular atrial fibrillation (NVAF) is the most common arrhythmia in older patients. Although direct-acting oral anticoagulants (DOAC) are the antithrombotic treatment of choice, irrespective of age, certain factors may limit their use. The aim of the ACONVENIENCE study was to consult the opinion of a multidisciplinary panel of experts on the appropriateness of using OACs in elderly patients (>75 years) with NVAF associated with certain complex clinical conditions. A consensus project was performed on the basis of a systematic review of the literature, and application of a two-round Delphi survey. The agreement of 79 panellists on 30 Delphi-type statements was evaluated, and their opinion on the appropriateness of different oral anticoagulants in 16 complex clinical scenarios was assessed. A total of 27 consensus statements were agreed upon, including all statements addressing anticoagulation in older patients and in patients at high risk of bleeding complications, and most of those addressing frailty, dementia, risk of falling, and complex cardiac situations. It was almost unanimously agreed upon that advanced age should not influence the anticoagulation decision. Apixaban was the highest-rated therapeutic option in 14/16 situations, followed by edoxaban. There is a high degree of agreement on anticoagulation in older patients with NVAF. Age should not be the single limiting factor when prescribing OACs, and the decision should be made based on net clinical benefit and a comprehensive geriatric assessment. Apixaban, followed by edoxaban, was considered the most appropriate treatment in the various complex clinical situations examined.
No takes yet. Share an insight, caveat, or question.
Bonanad et al. (2022) studied Non-valvular atrial fibrillation (NVAF) in elderly patients (≥75 years) with complex clinical conditions (n=79). Direct-acting oral anticoagulants (apixaban, edoxaban, rivaroxaban, dabigatran) vs. Vitamin K antagonists (VKAs) was evaluated on Expert consensus on 30 Delphi statements (≥80% agreement) and appropriateness ratings (scale 1-10) in 16 clinical scenarios. Apixaban was rated the most appropriate oral anticoagulant in 14 of 16 complex clinical scenarios in elderly NVAF patients, with 90% (27/30) of Delphi statements reaching expert consensus.
Synapse has enriched 10 related papers. Consider them for comparative context: